EMGEL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Emgel, and what generic alternatives are available?
Emgel is a drug marketed by Altana and is included in one NDA.
The generic ingredient in EMGEL is erythromycin. There are one hundred and three drug master file entries for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the erythromycin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Emgel
A generic version of EMGEL was approved as erythromycin by TORRENT on July 6th, 2020.
Summary for EMGEL
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 103 |
Patent Applications: | 7,074 |
Formulation / Manufacturing: | see details |
DailyMed Link: | EMGEL at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for EMGEL
US Patents and Regulatory Information for EMGEL
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Altana | EMGEL | erythromycin | GEL;TOPICAL | 063107-001 | Aug 23, 1991 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |